Private CNS Company Review for 2010 Released by NI Research

CARDIFF, CA--(Marketwire - January 20, 2010) -

NI Research, the publisher of NeuroInvestment, has released the 2010 edition of the Private CNS Company Review. The completely revised and updated 2010 edition provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders.

For each of the 102 companies covered, PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. Licensing and M&A opportunities are also compiled and appraised, as are rosters of company funding and VC financing. NI Research has published PCNS since 2003, and it has become a highly valued Business Development tool for the neuropharm industry.

Table of Contents for PCNS 2010: Introduction and Comment Private Company Fates/Casualties 2003-9 Private CNS Company Funding 2009 Scavenger Hunt PCNS Licensing Opportunities by Stage Top PCNS Licensing Opportunities Top PCNS M&A Opportunities Accera/Neuera AC Immune Acumen Pharmaceuticals Adamas Pharmaceuticals Affectis Pharmaceuticals Affiris Afraxis AgeneBio Alzhyme American Life Science Pharmaceuticals Archer Pharmaceuticals Arcion Therapeutics ArmaGen Technologies AurimMed Pharma Axon-Neuroscience Axxonis Pharma AG Azevan Pharmaceuticals Bayhill Therapeutics BioArctic Neuroscience BioChromix Pharma BrainCells BrainTact Cambria Pharmaceuticals Cara Therapeutics Cellzome CeNeRx BioPharma Ceregene Clera Cognition Pharmaceuticals Cognition Therapeutics Cognosci CoLucid CoMentis Embera Neurotherapeutics ENKAM Pharmaceuticals EnVivo Pharmaceuticals Galantos Pharma Galenea GliaMed Helicon Therapeutics/ Dart Neuroscience Intra-Cellular Therapies KeyNeurotek Kinexis Knopp Neurosciences Link Medicine Maas Biolab Medeia Therapeutics MedGenesis MediProPharma Mithridion M’s Science Neuraltus NeurAxon Neureva Neurim Neurimmune NeuroGeneration NeuroHealing NeuroKos Neuronascent NeuroNova NeuroProtect NeuroTherapeutics Pharma Neurotune AG NoNO Inc. Noscira NsGene NuPathe Oligomerix PharmaNeuroBoost Pharmaxon Pharnext Probiodrug ProMentis Pharmaceuticals Proneuron Biotechnologies Proteostasis Therapeutics Psyadon Pharmaceuticals Psylin Neuroscience Q Therapeutics RemeGenix SanBio Satori Pharmaceuticals SCT Spinal Cord Therapeutics Seaside Therapeutics Senexis Solace Pharmaceuticals Solstice Neurosciences Sonexa Therapeutics Spinifex Stealth Peptides Synosia Therapeutics TauRx TauTaTis TheraQuest Biosciences to-BBB Trophos Xenome Ltd Yaupon Therapeutics Zenobia Zogenix Programs by Company, Indication, Stage Company Funding VC Funding Roster 

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics since 2007. NI Research also provides licensing consultation and research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

To download PCNS 2010 information/order form: http://www.niresearch.com/PCNS 2010 order.pdf